Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05959551
Other study ID # HS24853
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date August 31, 2025

Study information

Verified date June 2023
Source University of Manitoba
Contact Ji Hyun Ko, PhD
Phone 2042930724
Email ji.ko@umanitoba.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the proposed study is to broaden our understanding on the neural effects of High Definition Transcranial Direct Current Stimulation (HD-tDCS) so that its clinical effects can be further improved.


Description:

Normal healthy individuals will be recruited and undergo a standardized neuropsychological assessment (ANAM, MoCA, BDI-II, ToMS, and MAAS) and magnetic resonance imaging (MRI). During MRI, HD-tDCS will be applied. Four different stimulation targets will be investigated, and subjects will be randomly assigned for each target groups or sham group. After HD-tDCS/MRI session, subjects will be re-assessed with standardized neuropsychological tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All other than excluded. Exclusion Criteria: - History or susceptibility to any neurological or psychiatric diseases, particularly seizures - abnormal MRI - metal implants or a cardiac pacemaker - pregnant or breastfeeding women

Study Design


Related Conditions & MeSH terms


Intervention

Device:
high definition transcranial direct current stimulation (HD-tDCS)
HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.

Locations

Country Name City State
Canada University of Manitoba Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
University of Manitoba Natural Sciences and Engineering Research Council, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary change of functional connectivity Changes in seed-based connectivity originating from the targeted brain regions immediately after the brain stimulation 0-11 minutes after the stimulation contrasting baseline (before stimulation)
Secondary change of cerebral blood flow Changes in Cerebral Blood Flow (estimated using pseudo continuous arterial spin labeling ) 12-16 minutes after the stimulation contrasting baseline (before stimulation)
Secondary Toronto Mindfulness Scale (curiosity) mindfulness scale for curiosity. min: 0, max: 30. Higher score means higher curiosity-mindfulness. Baseline, then within 1-2 hours from stimulation
Secondary Toronto Mindfulness Scale (decentering) mindfulness scale for decentering. min: 0, max: 35. Higher score means higher decentering-mindfulness. Baseline, then within 1-2 hours from stimulation
See also
  Status Clinical Trial Phase
Completed NCT03287037 - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression N/A
Recruiting NCT06419517 - Pelvic Muscle Training and Electrostimulation to Treat Weak Pelvic Floor N/A
Completed NCT05966922 - Transcutaneous Electrical Stimulation & Sinoatrial Node Function N/A
Completed NCT05261919 - Relationship Between Acupuncture Needling Direction and Electric Current N/A